Skip to Content

Posts tagged with "Business and Markets"

  • Business and Markets

    The Business End and the Science End

    Enough depression for now. The last couple of posts have not been cheerful, because there’s a lot of not-so-cheerful stuff out there in the business side of the industry. But I wanted to remind everyone (and myself) that we’re actually getting some good things done around here. Take a look at oncology – it’s starting… Read More
  • Business and Markets

    Onyx Site Closed Down

    Let’s get the bad news out of the way first. Amgen’s purchase of Onyx now has the widely expected sequel: they’re closing down that site, and laying off 300 people. Kyprolis is working out fine, and that’s all Amgen wanted. The only surprise, sadly, is that it took them this long. Read More
  • Business and Markets

    The New, Nasty, Normal

    This is not a happy column by John Carroll at FierceBiotech. But it’s an accurate one. He references the period just a few years ago when Pfizer closed its Sandwich site in the UK and Roche closed Nutley, NJ, among other upheavals. That period of intense Big Pharma turmoil, though, has failed to create a… Read More
  • Business and Markets

    Shire Layoffs Soon?

    This isn’t sounding so good, either. Shire is moving its Pennsylvania site, relocating people to the main campus in Lexington, Massachusetts, but now it appears that quite a few of them won’t be making the trip: The biotech filed a WARN letter with the state of Pennsylvania outlining plans to downsize its operations at its… Read More
  • Business and Markets

    Merck Strips Out Cubist

    Remember Merck buying Cubist? And the problems that immediately came up around the company’s patent estate? Merck stuck to their decision, with lots of talk about how they were committed to it no matter what, but one always had to wonder what the sequel would be. Here’s David Shlaes at the time: This announcement is… Read More
  • Business and Markets

    Twenty-One Billion Dollars. Really.

    Ibrutinib seems to be worth even more than everyone thought! As of this morning, AbbVie has won what was apparently a lively bidding war for Pharmacyclics, paying $21 billion for the company. Now that is a lot of money, and I’m not sure that I can made those numbers add up, but presumably there are… Read More
  • Business and Markets

    AZ Spins Off Anti-Infectives

    Word came yesterday that AstraZeneca is spinning off its anti-infectives division into a separate subsidiary company. This does not appear to have been their first choice – they’ve been shopping these assets around for actual cash, but had no takers (at least, on their terms). Here’s what they’re telling the employees: . . . Read More
  • Business and Markets

    All That Cash

    From the LifeSciVC blog, here’s a revealing comparison of the amount of money going into startups in this business. This is why I tend to get worked up about the number of stock buyback plans among the big pharma players. It would seem that there is so much cash sloshing around on the balance sheets… Read More
  • Business and Markets

    Cutbacks at Merck Serono

    Merck/Serono (Merck KGaA of Darmstadt) is apparently cutting back in Billerica, their US research site. According to FierceBiotech, though, they’re not saying by how much: “a limited number of discovery positions have been impacted in our research organization. We are working to re-assign as many of those positions as possible in the or… Read More
  • Business and Markets

    Bonne Chance, Brandicourt

    Sanofi’s CEO hunt has ended, and the roue de la fortune has pointed to Bayer’s Olivier Brandicourt. (I’m tempted to keep dropping French phrases every couple of lines, but I figure that no one will stand for it, so you can work them in mentally as appropriate). But before his two years at Bayer, Brandicourt… Read More
...192021...